上海新阳 reported revenue of ¥1.20B for the period ended 2026-06-30, +33.7% year on year. Net income was ¥0.21B, a 17.8% net margin on a 42.3% gross margin. The largest revenue line is 集成电路材料 at 83% of the total. Free cash flow for the period was ¥-0.04B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.20B | +33.7% |
| Gross profit | ¥0.51B | — |
| Operating income | ¥0.22B | — |
| Net income | ¥0.21B | +59.9% |
| Gross margin | 42.3% | Net margin 17.8% |
| Revenue Q/Q | +7.6% | — |
| Segment | Revenue | Share |
|---|---|---|
| 集成电路材料 | ¥0.99B | 83.0% |
| 涂料品 | ¥0.21B | 17.3% |
| 集成电路材料配套设备及配件 | ¥0.04B | 3.7% |
| 集成电路电镀加工 | ¥0.02B | 1.3% |
| 其他(补充) | ¥0.00B | 0.3% |
| 内部抵消 | ¥-0.07B | -5.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.69B | 57.7% |
| R&D | ¥0.16B | 13.6% |
| SG&A | ¥0.14B | 11.6% |
| Tax & other | ¥0.00B | 0.2% |
| Item | Amount |
|---|---|
| Total assets | ¥8.91B |
| Total liabilities | ¥2.07B |
| Shareholders' equity | ¥6.84B |
| Equity / assets | 76.8% |
| Operating cash flow | ¥0.15B |
| Capital expenditure | ¥0.19B |
| Free cash flow | ¥-0.04B |
| Cash conversion (OCF / net income) | 87% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
ST美晨 ・ 冠昊生物 ・ 东宝生物 ・ 飞力达 ・ 瑞丰光电 ・ 佳云科技 ・ 瑞丰高材 ・ 迪安诊断 ・ ST天玑 ・ 宝莱特 ・ 融捷健康 ・ 新开普
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies